The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | ICONIC: FLOT-A in resectable oesophagogastric adenocarcinoma
Avani Athauda, MBBS, MRCP, The Royal Marsden NHS Foundation Trust, London, UK, presents results of an interim safety analysis of 15 patients from the ongoing ICONIC study (NCT03399071), a single-arm Phase II trial investigating the safety and efficacy of periperative FLOT in combination with avelumab, an anti-PD-L1 antibody in patients with resectable esophagogastric adenocarcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
